Inflammation-induced S100A8 activates Id3 and promotes colorectal tumorigenesis

The aberrant expression of S100A8 and S100A9 is linked to nonresolving inflammation and ultimately to carcinogenesis, whereas the underlying mechanism that allows inflammation to progress to specific cancer types remains unknown. Here, we report that S100A8 was induced by inflammation and then promoted colorectal tumorigenesis downstream by activating Id3 (inhibitor of differentiation 3). Using gene expression profiling and immunohistochemistry, we found that both S100A8 and S100A9 were upregulated in the chemically-induced colitis-associated cancer mouse model and in human colorectal cancer specimens. Furthermore, we showed that S100A8 and S100A9 acted as chemoattractant proteins by recruiting macrophages, promoting the proliferation and invasion of colon cancer cell, as well as spurring the cycle that culminates in the acceleration of cancer metastasis in a nude mouse model. S100A8 regulated colon cancer cell cycle and proliferation by inducing Id3 expression while inhibiting p21. Id3 expression was regulated by Smad5, which was directly phosphorylated by Akt1. Our study revealed a novel mechanism in which inflammation-induced S100A8 promoted colorectal tumorigenesis by acting upstream to activate the Akt1-Smad5-Id3 axis. What's new? It hasn't been clear why chronic inflammation may progress to colitis-associated cancers (CAC). In this study, the authors found that the inflammatory factor S100A8 contributes to CAC tumorigenesis through the Akt1-Smad5-Id3 signaling pathway. Id3 and other Id proteins are transcription factors that play an important role in angiogenesis, inflammation, proliferation, and migration in several common types of cancer. The finding that dysregulated S100A8 expression activates Id3 provides a novel link between inflammation and cancer.